Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: A report from the Eastern Cooperative Oncology Group

Mark R. Litzow, Megan Othus, Larry D. Cripe, Steven D. Gore, Hillard M. Lazarus, Sandra J. Lee, John M. Bennett, Elisabeth M. Paietta, Gordon W. Dewald, Jacob M. Rowe, Martin S. Tallman

Research output: Contribution to journalArticle

Abstract

The treatment of relapsed acute myeloid leukaemia (AML) remains unsatisfactory. We conducted a phase II randomized trial where patients received intermediate-dose cytarabine for 4 d followed by gemtuzumab ozogamicin on day 5 (Arm A), or combined with liposomal daunorubicin for 3 d (Arm B), or cytarabine given for 5 d combined with cyclophosphamide for 3 d and topotecan by continuous infusion for 5 d (Arm C). Eligible patients had primary refractory AML, a first relapse after a remission of

Original languageEnglish (US)
Pages (from-to)217-225
Number of pages9
JournalBritish Journal of Haematology
Volume148
Issue number2
DOIs
StatePublished - Jan 2010

Fingerprint

Cytarabine
Acute Myeloid Leukemia
Topotecan
Dilatation and Curettage
Daunorubicin
Cyclophosphamide
Recurrence
Therapeutics
gemtuzumab

Keywords

  • Acute myeloid leukaemia
  • Gemtuzumab ozogamicin
  • Liposomal daunorubicin
  • Relapse
  • Topotecan

ASJC Scopus subject areas

  • Hematology

Cite this

Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia : A report from the Eastern Cooperative Oncology Group. / Litzow, Mark R.; Othus, Megan; Cripe, Larry D.; Gore, Steven D.; Lazarus, Hillard M.; Lee, Sandra J.; Bennett, John M.; Paietta, Elisabeth M.; Dewald, Gordon W.; Rowe, Jacob M.; Tallman, Martin S.

In: British Journal of Haematology, Vol. 148, No. 2, 01.2010, p. 217-225.

Research output: Contribution to journalArticle

Litzow, MR, Othus, M, Cripe, LD, Gore, SD, Lazarus, HM, Lee, SJ, Bennett, JM, Paietta, EM, Dewald, GW, Rowe, JM & Tallman, MS 2010, 'Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: A report from the Eastern Cooperative Oncology Group', British Journal of Haematology, vol. 148, no. 2, pp. 217-225. https://doi.org/10.1111/j.1365-2141.2009.07917.x
Litzow, Mark R. ; Othus, Megan ; Cripe, Larry D. ; Gore, Steven D. ; Lazarus, Hillard M. ; Lee, Sandra J. ; Bennett, John M. ; Paietta, Elisabeth M. ; Dewald, Gordon W. ; Rowe, Jacob M. ; Tallman, Martin S. / Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia : A report from the Eastern Cooperative Oncology Group. In: British Journal of Haematology. 2010 ; Vol. 148, No. 2. pp. 217-225.
@article{134a13b64f9f4d7091f14f4576ba370a,
title = "Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: A report from the Eastern Cooperative Oncology Group",
abstract = "The treatment of relapsed acute myeloid leukaemia (AML) remains unsatisfactory. We conducted a phase II randomized trial where patients received intermediate-dose cytarabine for 4 d followed by gemtuzumab ozogamicin on day 5 (Arm A), or combined with liposomal daunorubicin for 3 d (Arm B), or cytarabine given for 5 d combined with cyclophosphamide for 3 d and topotecan by continuous infusion for 5 d (Arm C). Eligible patients had primary refractory AML, a first relapse after a remission of",
keywords = "Acute myeloid leukaemia, Gemtuzumab ozogamicin, Liposomal daunorubicin, Relapse, Topotecan",
author = "Litzow, {Mark R.} and Megan Othus and Cripe, {Larry D.} and Gore, {Steven D.} and Lazarus, {Hillard M.} and Lee, {Sandra J.} and Bennett, {John M.} and Paietta, {Elisabeth M.} and Dewald, {Gordon W.} and Rowe, {Jacob M.} and Tallman, {Martin S.}",
year = "2010",
month = "1",
doi = "10.1111/j.1365-2141.2009.07917.x",
language = "English (US)",
volume = "148",
pages = "217--225",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia

T2 - A report from the Eastern Cooperative Oncology Group

AU - Litzow, Mark R.

AU - Othus, Megan

AU - Cripe, Larry D.

AU - Gore, Steven D.

AU - Lazarus, Hillard M.

AU - Lee, Sandra J.

AU - Bennett, John M.

AU - Paietta, Elisabeth M.

AU - Dewald, Gordon W.

AU - Rowe, Jacob M.

AU - Tallman, Martin S.

PY - 2010/1

Y1 - 2010/1

N2 - The treatment of relapsed acute myeloid leukaemia (AML) remains unsatisfactory. We conducted a phase II randomized trial where patients received intermediate-dose cytarabine for 4 d followed by gemtuzumab ozogamicin on day 5 (Arm A), or combined with liposomal daunorubicin for 3 d (Arm B), or cytarabine given for 5 d combined with cyclophosphamide for 3 d and topotecan by continuous infusion for 5 d (Arm C). Eligible patients had primary refractory AML, a first relapse after a remission of

AB - The treatment of relapsed acute myeloid leukaemia (AML) remains unsatisfactory. We conducted a phase II randomized trial where patients received intermediate-dose cytarabine for 4 d followed by gemtuzumab ozogamicin on day 5 (Arm A), or combined with liposomal daunorubicin for 3 d (Arm B), or cytarabine given for 5 d combined with cyclophosphamide for 3 d and topotecan by continuous infusion for 5 d (Arm C). Eligible patients had primary refractory AML, a first relapse after a remission of

KW - Acute myeloid leukaemia

KW - Gemtuzumab ozogamicin

KW - Liposomal daunorubicin

KW - Relapse

KW - Topotecan

UR - http://www.scopus.com/inward/record.url?scp=72649098720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72649098720&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2009.07917.x

DO - 10.1111/j.1365-2141.2009.07917.x

M3 - Article

C2 - 19804455

AN - SCOPUS:72649098720

VL - 148

SP - 217

EP - 225

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -